Medicare can pay for the popular weight-loss drug Wegovy — as long as the patients using it also have heart disease and need to reduce the risk of future heart attacks, strokes and other serious problems, federal officials said Thursday.
The Centers for Medicare & Medicaid Services issued new guidance that says Medicare Part D drug benefit plans — which are offered through private insurers — could cover anti-obesity drugs that are approved for an additional use.
The move could pave the way for thousands of new prescriptions, resulting in billions of dollars in increased spending, analysts have said.
In practice, the guidance opens the door to wider coverage of Wegovy, the brand name of Novo Nordisk’s obesity medication semaglutide. The U.S. Food and Drug Administration this month approved a label change that allows Wegovy to be used to reduce the risk of cardiovascular events in people who are overweight or have obesity and also have existing heart disease.
Related articles:
Related suggestion:
Orbán challenger in Hungary mobilizes thousands at a rare demonstration in a government strongholdSpice Girl Mel C is surrounded by eager fans as she lands at Sydney Airport amid Australian DJ tourSpain's Botin beats heavyweights Burling and Slingsby to win Bermuda Sail Grand PrixWarren Buffett's company faces lawsuit over shareholder proposalMexico recovers bodies likely those of missing surfersStephen A. Smith hits back at exIndian separatists plotted to kill Sir Winston Churchill during preI did everything right but still almost died on a bushwalk. Here's how I survivedLemi Berhanu Hayle wins Prague international marathon, Bedatu Hirpa Badane claims women's raceViolence breaks out at Leeds University as pro
3.1397s , 6501.1875 kb
Copyright © 2024 Powered by Medicare can pay for obesity drugs like Wegovy in certain heart patients ,Worldly Window news portal